Condition: Indirect Pulp Cap · Pulpotomy · Sponsor: Geisinger Clinic
The purpose of this prospective study is to compare the clinical and radiographic success of MTA and Biodentine as a medicament in vital pulp therapy in maxillary and mandibular primary molars in a pediatric population. There is limited research currently on Biodentine since it's a novel product. Biodentine is less expensive than MTA and does not cause discoloration like MTA. Biodentine may be an alternative medicament used for vital pulp therapy in primary molars.
This description comes directly from the study's public registry record.
Gayatri Malik, DMD · 570-271-6355 · gmalik1@geisinger.edu
Samantha R Crissinger · 570-271-7499 · srcrissinger@geisinger.edu
Always discuss trial participation with your own doctor first.
| Geisinger | Danville, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04863222